Global healthcare experts call for an R&D fund and mechanism for "neglected" diseases

13 May 2015

A group of global health experts including those from humanitarian group Médecins Sans Frontières and the Drugs for Neglected Diseases Initiative are calling for the creation of a global research and development fund to help address deadly gaps in innovation.

The representatives have highlighted threats such as Ebola, anti-microbial resistance and others that they see as currently being neglected by the pharma market, ahead of the World Health Assembly next week and the G7 Summit in June.

The experts argue in PLOS Medicine that recent proposals to tackle R&D gaps are too fragmented, and do not address issues of affordability and access in this process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >